Process Chemistry Ontology
1087 terms(s) returned
Term Type: | Record: 101 to 150 of 1087 Records | Page: 3 of 22, First Previous Next Last | Show Records Per Page |
- CQA specification
- CTA Section 3.2.S.1.1 Nomenclature
- CTA Section 3.2.S.1.2 Structure
- CTA Section 3.2.S.1.3 General Properties
- CTA Section 3.2.S.2.1 Manufacturers
- CTA Section 3.2.S.2.2 Description of Manufacturing Process and Process Controls
- CTA Section 3.2.S.2.3 Control of Materials
- CTA Section 3.2.S.2.4 Controls of Critical Steps and Intermediates
- CTA Section 3.2.S.3.1 Elucidation of Structure and other Characteristics
- CTA Section 3.2.S.3.2 Impurities
- Central Composite Design
- Contributor
- Control Strategy
- Creator
- Czochralski process
- DEREK Mutagen Prediction
- DNA polymerase activity
- DNA polymerase complex
- Date
- Davies condenser
- Description
- Dimroth condenser
- EC 1.* (oxidoreductase) inhibitor
- EC 1.9.* (oxidoreductase acting on donor heme group) inhibitor
- EC 1.9.3.* (oxidoreductase acting on donor heme group, oxygen as acceptor) inhibitor
- EC 1.9.3.1 (cytochrome c oxidase) inhibitor
- EC 3.* (hydrolase) inhibitor
- EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor
- EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor
- EC 3.5.1.4 (amidase) inhibitor
- Erlenmeyer flask
- Escherichia coli metabolite
- Format
- Frederichs condensor
- GLP synthetic process
- GMP specification of synthetic process
- GMP starting material
- GMP synthetic process
- Gibbs free energy change
- Gibbs free energy of activation
- Good's buffer substance
- Graham condensor
- ICH Guideline
- ICH M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk
- ICH Q11 Guidance for Development and Manufacture of Drug Substances
- ICH Q3A Impurities in New Drug Substances
- ICH Q3C Residual Solvents
- ICH Q3D Guidance for Elemental Impurities
- ICH Q6A Class 1 Solvent
- ICH Q6A Class 2 Solvent